Fierce Healthcare August 12, 2024
Heather Landi

Consumer genetic testing company 23andMe sees an opportunity to get in on the weight loss boom.

The company, through its Lemonaid Health business, plans to launch a GLP-1 weight loss telehealth membership by the end of the month, it announced last week along with its fiscal first-quarter financial results.

The service will enable members to be prescribed and receive brand-name or compounded semaglutide medications, the company said.

“The addition of weight loss management for our customers fits directly within our strategy of delivering services to improve an individual’s health through preventive actions. We also continue to add features to our membership services as we focus on creating longitudinal value that can help our members remain focused on improving their health,”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Pharma / Biotech, Technology, Telehealth
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old
U.S. Health Care Spending Reaches $4.9 Trillion

Share This Article